Chemotherapy with and without ivonescimab for advanced colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a new drug called ivonescimab to standard chemotherapy helps shrink advanced colon cancer before surgery. It may improve the chances of removing all the cancer and reduce the risk of it coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colon cancer that is locally advanced (has grown deep into the bowel wall or spread to nearby lymph nodes) but has not spread to distant organs.
- You have not had any prior treatment for your colon cancer.
- You are between 18 and 75 years old.
- You are generally able to take care of yourself (ECOG score 0 or 1).
- Your tumor is a type called pMMR or MSS (your doctor can check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This trial tests whether giving radiation therapy along with standard chemotherapy before surgery can help shrink advanced colon cancer that has grown through the bowel wall but hasn't spread to other organs. It is for a specific type of colon cancer called pMMR/MSS.
This clinical trial tests a new drug, ivonescimab, against an approved drug, bevacizumab. Both are given with standard chemotherapy (FOLFOX) for people with advanced colorectal cancer that has not been treated yet with chemo or other drugs.
This trial tests a new drug called ivonescimab combined with chemotherapy for people with metastatic colorectal cancer that has not spread to the liver. The goal is to see if this combination can help control the cancer better than chemotherapy alone.
This trial tests a new immunotherapy drug called ivonescimab given together with standard chemotherapy for advanced stomach cancer. It may help your immune system fight the cancer more effectively.
This trial tests a new drug called ivonescimab, which is a bispecific antibody that targets both PD-1 and VEGF. It is for people with metastatic colorectal cancer who have already tried standard treatments and may or may not have received immunotherapy before, depending on their tumor type.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.